Publications by authors named "J Calzas"
Background: Non-small cell lung cancer (NSCLC) accounts for the vast majority of all diagnosed lung cancers. According to their histology, most NSCLCs are considered non-squamous cell carcinoma (NSCC), and up to 85% of the latter may lack either one of the two main actionable oncogenic drivers (i.e.
View Article and Find Full Text PDFPurpose: Venous thromboembolism (VTE) is a leading cause of death among patients with cancer. The Khorana score was developed for assessing the risk of VTE in outpatients with cancer receiving chemotherapy, but its accuracy in identifying patients at high risk has been questioned. The aim of this study was to develop and validate a clinical-genetic score that improves the assessment of VTE risk in oncology outpatients within 6 months of diagnosis.
View Article and Find Full Text PDFBackground: Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ovarian cancer (OC). The Rucaparib Access Programme (RAP) was designed to provide early access to rucaparib for the above-mentioned indication, as well as for patients with BRCA-mutated Pt-S or platinum-resistant (Pt-R) OC and no therapeutic alternatives.
Methods: In this observational, retrospective study we analysed the efficacy and safety of rucaparib within the RAP in Spain.
Article Synopsis
- - Lung cancer survival rates in Spain have improved by about 15% in the last decade, largely due to advancements in targeted therapies and immunotherapy, prompting a study on biomarker testing in the country.
- - The study analyzed 9,239 patients with stage IV non-small cell lung cancer from 2016 to 2020, revealing that 85% of non-squamous patients underwent tumor marker testing, compared to 56.3% of squamous patients, with high positivity rates observed for key biomarkers.
- - Although Spain lacks a national protocol for biomarker testing, the findings align with trends in other European nations, highlighting the need for standardized strategies to optimize patient care amidst increasing numbers of determinations and positive results.*
Background: Small-cell lung cancer (SCLC) is an aggressive disease with high metastatic potential and poor prognosis. Due to its low prevalence, epidemiological and clinical information of SCLC patients retrieved from lung cancer registries is scarce.
Patients And Methods: This was an observational multicenter study that enrolled patients with lung cancer and thoracic tumors, recruited from August 2016 to January 2020 at 50 Spanish hospitals.